Literature DB >> 28099318

LOW ENDOPHTHALMITIS RATES AFTER INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR INJECTIONS IN AN OPERATION ROOM: A Retrospective Multicenter Study.

Florentina J Freiberg1, Troels Brynskov2, Marion R Munk3, Torben L Sørensen2, Sebastian Wolf3, Magdalena A Wirth1, Matthias Becker1, Stephan Michels1.   

Abstract

PURPOSE: To evaluate the rate of presumed endophthalmitis (EO) after intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections in three European hospitals performed in an operation room (OR) under sterile conditions.
METHODS: A retrospective multicenter study between 2003 and 2016 at three European sites, City Hospital Triemli Zurich, Switzerland (CHT), Zealand University Hospital Roskilde, Denmark (ZUH) and University Clinic Bern, Switzerland (UCB). Intravitreal injection (IVI) database of each department was reviewed. All anti-vascular endothelial growth factor injections were performed using a standardized sterile technique in an operation room. Injection protocols were similar between the three sites. No preinjection antibiotics were given. Postoperative antibiotics varied among sites.
RESULTS: A total of 134,701 intravitreal injections were performed at the 3 sites between 2003 and 2016. Ten cases of presumed endophthalmitis were documented: 4 in 50,721 at CHT (95% CI: 0.0071-0.0087%), 2 in 44,666 at ZUH (95% CI: 0.0039-0.0051%), and 4 in 39,314 at UCB (95% CI: 0.0092-0.011%). This results in one case in 13,470 intravitreal injections and a combined incidence of 0.0074% per injection (95% CI: 0.0070-0.0078%). Positive cultures were found in 4 out of 10 presumed endophthalmitis cases.
CONCLUSION: The standardized sterile technique in an operation room with laminar airflow showed very low rates of endophthalmitis at three European sites.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28099318     DOI: 10.1097/IAE.0000000000001488

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  9 in total

1.  Correspondence.

Authors:  Andrzej Grzybowski; Stephen G Schwartz; Nidhi Relhan; Harry W Flynn
Journal:  Retina       Date:  2017-09       Impact factor: 4.256

Review 2.  Endophthalmitis.

Authors:  Shwu Jiuan Sheu
Journal:  Korean J Ophthalmol       Date:  2017-06-28

3.  Targeted Delivery of FLT-Morpholino Using Cyclic RGD Peptide.

Authors:  Hironori Uehara; Santosh Kumar Muddana; Xiaohui Zhang; Subrata Kumar Das; Sai Bhuvanagiri; Jinlu Liu; Yuanyuan Wu; Susie Choi; Lara S Carroll; Bonnie Archer; Balamurali K Ambati
Journal:  Transl Vis Sci Technol       Date:  2017-05-24       Impact factor: 3.283

Review 4.  Current Evidence for the Prevention of Endophthalmitis in Anti-VEGF Intravitreal Injections.

Authors:  P Et Lau; K S Jenkins; C J Layton
Journal:  J Ophthalmol       Date:  2018-07-24       Impact factor: 1.909

5.  Can the dexamethasone intravitreal implant Ozurdex be safely administered in an out-of-operating room setting?

Authors:  María Del Pino Cidad-Betegón; Félix Armadá-Maresca; Gloria Amorena-Santesteban; Javier Coca-Robinot; Oriana D'Anna-Mardero; Irene de la Rosa-Pérez; Beatriz Manzano-Muñoz; Jesús García-Martínez; Mónica Asencio-Durán; Gema Casado-Abad
Journal:  J Drug Assess       Date:  2020-03-31

6.  Incidence of Endophthalmitis after Intravitreal Anti-Vascular Endothelial Growth Factor Injections in an Operating Room in China.

Authors:  Yanyun Chen; Wenbin Wei; Demetrios G Vavvas; Feng Zhang; Haicheng She; Haiying Zhou; Lei Li; Yao Huang; Dimitrios P Ntentakis; Xiangyu Shi
Journal:  J Ophthalmol       Date:  2020-11-12       Impact factor: 1.909

7.  Intravitreal Injections with Vascular Endothelial Growth Factor Inhibitors: A Practical Approach.

Authors:  Anne-Sofie Petri; Kirstine Boysen; Lasse J Cehofski; Elon H C van Dijk; Chantal Dysli; Josefine Fuchs; Rodolfo Mastropasqua; Yousif Subhi
Journal:  Ophthalmol Ther       Date:  2020-02-07

8.  Factors influencing harmonized health data collection, sharing and linkage in Denmark and Switzerland: A systematic review.

Authors:  Lester Darryl Geneviève; Andrea Martani; Maria Christina Mallet; Tenzin Wangmo; Bernice Simone Elger
Journal:  PLoS One       Date:  2019-12-12       Impact factor: 3.240

9.  Economic burden of age-related macular degeneration in routine clinical practice: the RAMDEBURS study.

Authors:  José M Ruiz-Moreno; Luís Arias; Maximino J Abraldes; Javier Montero; Patricia Udaondo
Journal:  Int Ophthalmol       Date:  2021-06-10       Impact factor: 2.031

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.